The clinical question behind India pharmaceutical market growth 2026 is whether more people are being diagnosed and treated, or whether the same patients are simply paying more. Domestic medicine sales rose 12% to ₹70,180 crore in the July to September 2026 quarter, according to PharmaTrac data cited in press reports, led by medicines for heart disease, diabetes and cancer. The data do not settle the question, but the therapy-level detail from a separate dataset gives clues. This article looks at what the numbers imply for chronic disease treatment, where the evidence is thin and what epidemiological data would be needed to test the claim that diagnosis is rising.
India pharmaceutical market growth 2026: the evidence in brief
- Domestic sales rose 12% to ₹70,180 crore, the fourth straight double-digit quarter, per PharmaTrac as reported.
- Greater diagnosis of chronic disease is cited as a driver, but reports say the contribution of each factor is not established.
- September data from Pharmarack show cardiac medicines up 17.7% (volumes up 9.1%), anti-diabetes up 16.1% and cancer drugs up 21.6%.
- In the same dataset, price growth of 6.2% outweighed volume growth of 3.5%.
- Anti-infectives rose only 5.8%, and respiratory volumes fell 6.9%.
What the therapy data suggest about India pharmaceutical market growth 2026
Volumes are the better proxy for the number of patients treated, and in the September Pharmarack data cardiac volumes grew 9.1%, well above the 3.5% for the market overall. That is consistent with more people taking heart medicines, though volume measures units sold and not patients, so one patient taking more tablets would also register. Anti-diabetes value grew 16.1%, helped, according to the reports, by new GLP-1 generics and oral combinations. The World Health Organization sets out the global scale of diabetes in its diabetes fact sheet. Figures for the quarter as a whole are available only for the total market.
Is diagnosis rising? Testing the India pharmaceutical market growth 2026 claim
Mankind Pharma’s managing director Rajiv Juneja said better access to tests and rising health awareness are lifting demand, according to the reports. If diagnosis were rising, one would expect to see growth in medicines used for newly found conditions, in diagnostic test volumes and in screening programmes. The market data capture only the medicine side. Survey evidence from national health surveys or registries would be needed to show that more people with hypertension or diabetes are now aware of their condition and on treatment. We have not reviewed such data for this article, so the diagnosis explanation should be seen as plausible but unproven.
Cancer and the India pharmaceutical market growth 2026 figures
Anti-neoplastic sales grew 21.6% in September in the Pharmarack data. Cancer medicines are expensive relative to most categories, so a small change in the number of patients or in the mix of newer drugs can move sales a lot. The reports do not break the increase into new patients, new products and price. Better detection and more access to treatment may play a role, but the sources do not provide evidence.
Cardiovascular medicines and the India pharmaceutical market growth 2026 data
Cardiac medicines are about 14% of the market in the Pharmarack data. Acumen Research and Consulting’s Hypertension Drugs Market report values the global hypertension drug market at USD 26.5 billion in 2023, rising to USD 38.3 billion by 2032, a CAGR of 4.2% for 2024 to 2032, with Asia Pacific growing at 5%. It notes that calcium channel blockers led in 2023 and that primary hypertension was a major revenue driver. The page was published in July 2024 and is global, so India’s faster current growth does not contradict it, but it is not Indian data.
Why the India pharmaceutical market growth 2026 numbers need caution
Eris Lifesciences managing director Amit Bakshi said part of the jump may reflect how trade generics and untraceable companies are captured in the data, and that such effects could account for 2 to 3 percentage points of structural growth. The regulator CDSCO has reportedly ordered hundreds of non-compliant small and mid-sized units to close over two years, and some of their sales may have moved to firms covered by the audit. These are measurement and market-structure effects and not changes in disease burden. We covered the differences between datasets in our report on September sales.
Anti-infectives and respiratory medicines in India pharmaceutical market growth 2026
Not every therapy is growing. Anti-infectives grew 5.8% and respiratory volumes fell 6.9% in September, attributed in the reports to the monsoon receding. Acute illnesses are seasonal and do not behave like chronic disease, so their weakness fits the story that chronic therapies are driving the market. It also means that headline growth can rise even if acute-care demand is flat.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Pharmaceutical Market report values the global market at USD 1.5 trillion in 2022 and projects USD 2.8 trillion by 2032, a CAGR of 6.4% for 2023 to 2032, with North America at about 38% and China and India named as key Asia Pacific contributors. The page also has a conflicting 38.4% CAGR bullet that it does not explain, and it dates from July 2024. It is useful as global context and not as a measure of India’s quarter.
Timeline of India pharmaceutical market growth 2026
- July to September 2025: growth about 7%.
- October 2025 to June 2026: 10% and then 11% in each of two quarters.
- July to September 2026: 12%, to ₹70,180 crore.
General background: price, volume and new-product effects
Analysts split pharma growth into price, volume and new launches. Volume is closest to patient numbers, price reflects annual increases and mix, and launches add new products. A market can grow quickly on price alone while treating no more patients.
Our analysis of India pharmaceutical market growth 2026
In our assessment, the evidence supports the view that chronic therapies are growing faster than acute ones, but not yet that diagnosis explains it. Volume growth of 3.5% is modest next to value growth of 13.5% in the monthly data, so price and mix carry much of the headline.
What is not disclosed about India pharmaceutical market growth 2026
- Patient-level or diagnosis data linking sales to new cases.
- A quarter-wide split of price, volume and launches.
- The effect of data-coverage changes on the headline.
Risks and caveats
This article relies on press reports of market data and general epidemiological reasoning and does not include survey evidence. It is news reporting and not medical advice.
What to watch next
- National survey results on hypertension and diabetes awareness and treatment.
- Volume trends in cardiac and diabetes medicines.
- Whether the next quarter keeps double-digit growth.
FAQ
Are more Indians being treated?
Cardiac volumes rose 9.1% in September, which is consistent with it, but the data cannot prove it.
Which therapy grew fastest?
Cancer drugs, up 21.6% in September in the Pharmarack data.
Is the 12% figure reliable?
It is a secondary citation of PharmaTrac data, and experts say coverage changes may inflate it.
How we reported this: we relied on press reports of PharmaTrac and Pharmarack data and company results, public pages from CDSCO and the WHO, and the Acumen Research and Consulting reports cited above. Last updated 2 November 2026. This is news reporting and not advice.
